{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Seroconversion was defined as achieving an anti-HPV Type 6 competitive Luminex Immunoassay (cLIA) level of \\>=20 milli Merck U/mL. The dilution-corrected limit of detection for the Type 6 cLIA was 4.2 milli Merck U/mL.","groups":[{"description":"GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A.","id":"OG000","title":"GARDASIL 9 to 26 Years Old"},{"description":"Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A.","id":"OG001","title":"Placebo 9 to 12 Years Old"}],"paramType":"NUMBER","populationDescription":"Participants analyzed included those who received all 3 vaccinations in study Phase A and provided a sample for Month 7 serology testing. This analysis pooled results for participants receiving GARDASIL and compared these with results for participants receiving placebo.","reportingStatus":"POSTED","timeFrame":"Month 7 (1 month postdose 3 in study Phase A)","title":"Number of Participants Who Seroconvert to Human Papillomavirus (HPV) Type 6","type":"PRIMARY","unitOfMeasure":"Participants"}